Genomic profiling of patients with metastatic castration-resistant prostate cancer (mCRPC) for the evaluation of rucaparib: Next-generation sequencing (NGS) of tumour tissue and cell-free DNA (cfDNA)

Authors :: Peter Ostler
D. Spaeth
Charles J. Ryan
I. Mejlholm
M.N. Reaume
Simon Chowdhury
E.R. Goldfischer
Raymond S. McDermott
A. Loehr
I. Byard
B. Laguerre
Elias Pintus
J.M. Piulats
Wassim Abida
David Campbell
E. Voog
A. Benjelloun
Arif Hussain
A. Reid
J. Burke
T. Golsorkhi
Simon Paul Watkins
Jeremy Shapiro
D. Morris
Source :: European Urology Supplements. 18:e469-e470
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: Genomic profiling
business.industry
Urology
Castration resistant
medicine.disease
DNA sequencing
Tumour tissue
chemistry.chemical_compound
Prostate cancer
Cell-free fetal DNA
chemistry
Cancer research
Medicine
business
Rucaparib

Full Text Access

Tools